瑞舒伐他汀钙对2型糖尿病患者血清C反应蛋白及血脂的影响

Effect of rasuvastatin calcium on dyslipldemia and hypersensitive C-reactive protein in diabetes patients

目的观察瑞舒伐他汀钙对糖尿病患者血脂异常的疗效及对高敏C反应蛋白(hs-CRP)和脂联素的影响。方法观察238例糖尿病伴有血脂异常的患者,其中治疗组119例,在严格控制血糖和低脂饮食的基础上,给予瑞舒伐他汀钙10 mg/d,睡前服,治疗24周;对照组119例,予严格控制血糖和低脂饮食。测定2组治疗前后的血糖、TG、TC、LDL-C、HDL-C、hs-CRP、脂联素水平,并进行比较分析。结果治疗组用药后与用药前比较,血糖无明显改变,TG下降(P<0.05),HDL-C有升高的趋势,但差异无统计学意义,TC下降[(4.45±0.69)mmol/L比(6.88±1.61)mmol/L P<0.01],LDL-C下降[(2.42±0.89)mmol/L比(4.92±1.45)mmol/L,P<0.01],hs-CRP明显下降[(4.38±1.69)mg/L比(7.51±3.52)mg/L,P<0.01],脂联素升高[(24.32±10.52)mg/L比(14.97±11.39)mg/L,P<0.01]。与对照组治疗后比较,治疗组的TC、LDL-C、TG和hs-CRP明显降低,差异有统计学意义(P<0.05或P<0.01),脂联素升高,差异有统计学意义(P<0.01),血糖差异无统计学意义。结论瑞舒伐他汀钙可有效地改善糖尿病患者血脂异常和炎症状态,可明显减轻糖尿病患者的动脉粥样硬化程度,其抗炎作用机制可能与降低hs-CRP水平,升高血清脂联素水平有关。

Objective To investigate the effect of rasuvastatin calcium on dyslipidemia and hypersensitive C-reactive protein in diabetes patients. Methods Two hundred and thirty-eight diabetes paties with dyslipidedmia were divided into two groups：control group and treatment group. All patients were in low-fat and lowcholesterol diet and controled blood glucose treatment as usual. Patients intreatment group took rasuvastatin （ 10 mg/day） for 24 weeks. Fasting blood glucose（ FBG）, Non-fasting blood glucose（NFBG） , Glycosylated hemoglo- bin A1 （GHbA1）, Serum total glycerin （TG）, total cholesterol（ TC ）, low-dense-lipoprotein cholesterol （LDL-C）, high-dense-lipoprotein cholesterol（ HDL-C）, hypersensitive C-reactive protein （hs-CRP） and adiponectin were measured before and after thetreatment. Results In patients with rasuvastatin treatment, TG was reduced, P 〈 0. 05） ,TC was reduced[ （4. 45 ±0. 69） mmol/L VS （6. 88± 1.61 ） mmol/L,P 〈0. 01 ] ,LDL-C was reduced [ （2.42 ± 0. 89 ） mmol/L VS （4. 92 ±1.45 ） mmol/L, P 〈 0.01 ], hs-CRP was significantly reduced [ （4. 38 ± 1.69） mg/L VS （7.51± 3.52 ） mg/L, P 〈 0.01 ], adiponectin was increased [ （24. 32 ± 10. 52 ） mg/L VS （ 14. 97 ± 11.39） rag/L, P 〈 0. 01 ]. Compared to control group, TC, LDL-C, and hs-CRP were significantly reduced in treatment group. Adiponectin was significantly increased in treatment group. There was no significant difference in HDL-C,FBG, NFBG, GHbA1. Conclusion Rasuvastatin Can decrease hypersensitive C-reactive protein and defer the development of atherosclerotic in diabetes patients with dyslipidemia. Anti-inflammatory mechanism maybe associated with decreasing the level of hs-CRP and increasing the serum adiponectin.